Pharma & Biotech

The NeuraMetrix solution provides Biopharmaceutical and Biotech companies with a much more precise, accurate, and cost-effective Digital Cognitive Biomarker for Clinical Drug Development
pharmaceutical sales rep meeting with a pharma company

The Clinical Trials Gap in Neurology and Psychiatry

Neurodegenerative diseases and psychiatric disorders create a major and growing challenge for healthcare. A key limitation in brain health and drug development is the lack of scalable, objective, continuous measurement of cognition and related functions.
Current Challenges
  • Clinical-trial measurements can be subjective, imprecise, variable, and difficult to repeat, reducing statistical quality.
  • Early indicators of treatment safety and efficacy are often limited.
  • Trials may enroll patients after disease progression has advanced beyond the point where a treatment can have a meaningful impact.
  • There is limited ability to monitor each participant's response in real time or measure cognitive side effects.
  • Neurology and psychiatry diagnoses can be difficult, and trial participation can impose a substantial burden through repeated clinic visits and testing.
  • Traditional cognitive assessments provide episodic snapshots rather than continuous, longitudinal data against an individual's baseline.

NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry

The NeuraMetrix Approach

​​​​​​​The NeuraMetrix passive digital brain-health biomarker collects information continuously during normal daily activity, including keyboard use, without requiring formal cognitive tests. This provides a low-burden, remote and longitudinal measurement layer that can complement conventional clinical-trial assessments.
  • Objective, sensitive measures of disease state, progression, symptoms, and response to therapy.
  • Individual baselines and longitudinal monitoring of cognitive and motor changes in real-world settings.
  • Disease-specific digital fingerprints that can support comparison with patient data and verification of diagnosis.
  • Granular symptom quantification and patient segmentation to support prognostic and predictive enrichment.
  • Identification of responders and non-responders and monitoring of treatment adherence and other relevant variables.
  • Pre-randomization run-in measurements to identify spontaneous symptom resolution or highly variable baseline symptoms.
  • Automated, easy-to-use monitoring with minimal patient burden.
Potential Impact on Clinical Trials
  • Broader, more representative recruitment through remote measurement.
  • Smaller, faster, and potentially more statistically powerful trials through reduced variability and heterogeneity.
  • Earlier signals regarding treatment response and trial direction, supporting faster go/no-go decisions.
  • More responsive trial management, including informed sample-size adjustments and closer monitoring of participants.
  • Better identification of appropriate participants and disease stages for treatment studies.
  • Ability to measure cognitive side effects of their therapeutics
  • Reduced participant burden and potentially fewer dropouts.
  • Lower trial risk and cost.

Bottom Line


NeuraMetrix addresses the clinical-trial measurement gap by shifting from occasional, burdensome cognitive snapshots toward continuous, low-burden, real-world measurement. The resulting longitudinal data can support individual baselines, earlier detection of change, objective assessment of interventions, and more scalable clinical-trial designs.
//

"For the Brain Economy to deliver, cognitive testing and clinical trials both need to scale


- Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains.
Source
​​​​​​​